Oppenheimer & Co’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Oppenheimer & Co’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,920	Closed	-$210K	–	1312
2019 Q2	$210K	Sell	3,920 -245	-6%	-$12.7K	0.01%	1165
2019 Q1	$230K	Sell	4,165 -650	-13%	-$34.4K	0.01%	1161
2018 Q4	$227K	Buy	4,815 +100	+2%	+$5.14K	0.01%	1057
2018 Q3	$281K	Sell	4,715 -436	-8%	-$25.4K	0.01%	1092
2018 Q2	$282K	Buy	+5,151	New	+$262K	0.01%	1081
2015 Q2	–	Sell	-6,104	Closed	-$337K	–	1531
2015 Q1	$337K	Sell	6,104 -1,863	-23%	-$101K	0.01%	1056
2014 Q4	$400K	Buy	7,967 +625	+9%	+$30.6K	0.01%	913
2014 Q3	$339K	Buy	7,342 +526	+8%	+$23.7K	0.01%	1020
2014 Q2	$298K	Buy	6,816 +995	+17%	+$40.3K	0.01%	1056
2014 Q1	$242K	Sell	5,821 -226	-4%	-$9.67K	0.01%	1142
2013 Q4	$224K	Buy	+6,047	New	+$217K	0.01%	1158

Other funds holding PBE

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

Oppenheimer & Co's PBE Position: Q3 2019 in Review

Oppenheimer & Co sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2019, closing a stake of 3,920 shares — an estimated $210K sold.

Oppenheimer & Co first reported a position in PBE in Q4 2013 and held it in 11 quarters. The position peaked at $400K in Q4 2014. 73 funds tracked by Wall St. Rank hold PBE as of Q3 2019.

Oppenheimer & Co reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2019 after selling out during the quarter.
Oppenheimer & Co sold 3,920 Invesco Biotechnology & Genome ETF shares in Q3 2019, an estimated $210K.
Oppenheimer & Co first reported a position in Invesco Biotechnology & Genome ETF in Q4 2013 and held it in 11 quarters.
Oppenheimer & Co's Invesco Biotechnology & Genome ETF position peaked at $400K in Q4 2014.
73 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2019.

Based on Oppenheimer & Co's 13F filing for Q3 2019, filed 31 Oct 2019.